| Long name: |
GLCNE Primary Polyclonal Antibody |
| Also known as: |
GLCNE PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
GLCNE |
| Specificity: |
This is a highly specific antibody against GLCNE |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human GLCNE |
| Gene ID number: |
10020 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Both IBM2 and NM/DMRV are autosomal recessive neuromuscular disorders characterized by adult onset, Defects in GLCNE are the cause of sialuria, GLCNE is required for normal sialylation in hematopoietic cells, It is also expressed, It is characterized by an accumulation of free sialic acid in the cytoplasm and large quantities of neuraminic acid in the urine, It is upregulated after PKC-dependent phosphorylation and is most abundantly expressed in liver and placenta, Sialuria is an autosomal dominant disorder caused by a lack of feedback inhibition of GLCNE by CMP-NeuAc, Sialylation is implicated in cell adhesion, a precursor of sialic acids, brain, distal and proximal muscle weakness (especially in the legs) and a typical muscle pathology including filamentous inclusions and rimmed vacuoles, in heart, inclusion body myopathy 2 (IBM2) and Nonaka myopathy (NM) or distal myopathy with rimmed vacuoles (DMRV), kidney, lung, or GLCNE, regulates and initiates biosynthesis of N-acetylneuraminic acid (NeuAc), resulting in overproduction of NeuAc, signal transduction, skeletal muscle and pancreas, to a lesser extent, tumorigenicity and metastatic behavior of malignant cells, The bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE/Mnk) |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
Bunctional UDP N acetylglucosamine 2 epimerase/N acetylmannosamine kinase, DMRV, GLCNE_HUMAN, ManAc kinase, N acylmannosamine kinase, NM, RP23-209M8, UDP GlcNAc 2 epimerase, UDP GlcNAc 2 epimerase/ManAc kinase, Uae1, Uridine diphosphate N acetylglucosamine 2 epimerase, 6, IBM2 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
GLCNE |
| Short name: |
GLCNE Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
GLCNE (Antibody to) |
| Alternative technique: |
antibodies |